Illumina

Truveta is a healthcare data platform that collaborates with physicians, life science researchers, and healthcare organizations to aggregate and analyze medical records information. By compiling data from multiple healthcare systems, Truveta de-identifies and organizes this information to provide valuable medical insights. The platform initially focused on COVID-19, aiming to expedite research efforts, enhance clinician expertise, and support families in making informed healthcare decisions. Through its innovative approach, Truveta connects treatments with outcomes and various health factors, contributing to advancements in medical research and patient care.

Biomolecules are the next bits of the 21st century. So we're developing the first wet operating system for storing, accessing, and computing biomolecules at scale to make them widely accessible and useful. We're enabling the storage and access to the whole data universe—digital and biological—forever so that we don't have to delete or dispose of anything ever again.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which combines computational biology, wet lab techniques, and automation. This innovative approach allows for the design, testing, and optimization of TEVs tailored for specific therapeutic applications across diverse tissue and cellular targets. In addition to its engineering capabilities, Mantra Bio has established a scalable biomanufacturing process to ensure that these novel therapeutics can be produced reproducibly and with high purity, aiming to address intractable diseases effectively.

Neurolytic Healthcare Ltd. is a medical technology company based in Oxford, United Kingdom, specializing in the design, development, and manufacture of digital and genomic-based diagnostic tools and medical devices for migraine and related neurological disorders. Founded in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnosis and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed to predict migraine events. By leveraging artificial intelligence, Neurolytic Healthcare aims to provide genomics-driven diagnostics and personalized treatment recommendations, helping patients find effective treatments while minimizing side effects and reducing the trial-and-error approach often associated with neurological care.

IDbyDNA, Inc. is a company specializing in metagenomics technologies aimed at identifying infectious diseases. Founded in 2014 and based in Salt Lake City, Utah, it has developed a platform called Explify, which enables laboratories to detect and characterize pathogens using nucleic acid-based techniques. The company offers comprehensive testing services, including respiratory and research services, catering to hospitals, reference labs, clinical research institutions, and the biopharmaceutical sector. By leveraging computational biology and artificial intelligence, IDbyDNA strives to enhance diagnostic accuracy and treatment precision for infectious diseases, addressing the growing global challenge posed by these conditions.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50, and DAC, a diagnostic aid that enhances the resolution of cancer testing for patients with clinical suspicion of cancer. The company’s signature product is a multi-cancer early detection blood test that utilizes high-intensity sequencing to measure circulating nucleic acids, allowing for the identification of various cancer types at early stages. GRAIL is also working on developing minimal residual disease tests and other post-diagnostic assessments to further enhance cancer detection and treatment.

Enancio SAS, founded in 2017 and based in Cesson-Sévigné, France, specializes in genomic data compression software. The company's product, Lena, enhances the speed and efficiency of next-generation sequencing (NGS) analyses, significantly reducing storage costs and minimizing internal network traffic while maintaining data integrity. As a subsidiary of Illumina, Enancio’s solutions complement Illumina’s existing informatics offerings, providing users with optimal performance in genomic data management.

Bluebee is a prominent provider of high-performance genomics solutions that facilitate significant reductions in both costs and time-to-diagnosis for research and clinical laboratories. The company offers a cloud-based accelerated genomics platform designed for the fast and efficient processing of large volumes of genomic data. In light of transformative advancements in next-generation DNA sequencing technology, Bluebee addresses the challenges of handling increasing data volumes, the need for rapid data processing, and the demand for flexibility and reliability across diverse applications. By combining expertise in the field of genomics with high-performance computing and clinical-grade security, Bluebee's platform empowers healthcare institutions to explore new diagnostic methods and therapeutic options.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50, and DAC, a diagnostic aid that enhances the resolution of cancer testing for patients with clinical suspicion of cancer. The company’s signature product is a multi-cancer early detection blood test that utilizes high-intensity sequencing to measure circulating nucleic acids, allowing for the identification of various cancer types at early stages. GRAIL is also working on developing minimal residual disease tests and other post-diagnostic assessments to further enhance cancer detection and treatment.

Edico Genome Inc. specializes in the development of bioinformatics processor chips focused on DNA analysis. The company's primary product, the DRAGEN platform, utilizes a field-programmable gate array to accelerate genome pipeline algorithms, including tasks such as BCL conversion, mapping, alignment, and variant calling. This technology enhances the efficiency of analyzing next-generation sequencing data, facilitating healthcare institutions in identifying connections between DNA sequence variations and human diseases. Founded in 2013 and headquartered in La Jolla, California, Edico Genome operates as a subsidiary of Illumina, Inc. since May 2018.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Helix is a prominent population genomics company that focuses on integrating genomic data into clinical care, research, and public health. Its comprehensive platform facilitates large-scale genetic analysis and actionable insights, serving health systems, life sciences companies, payers, and government organizations. Helix operates one of the largest CLIA and CAP-certified next-generation sequencing laboratories and employs its proprietary Exome+™ assay to support various aspects of population genomics. This includes recruitment and engagement, clinically actionable disease screening, and the return of results, as well as basic and translational research. By advancing genomic research and enhancing patient care, Helix plays a critical role in shaping healthcare through genetics.

Prospect Bio is a synthetic biology company based in Brisbane, California, that focuses on developing biosensors for the detection of small molecules. These biosensors, which utilize living cells, offer a cost-effective, scalable, and field-deployable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. The company's innovative approach aims to transform testing processes across various industries, driven by the need for improved quality control and compliance with regulatory standards. Prospect Bio collaborates with a diverse range of partners, including major players in the wine industry, agriculture, and prenatal diagnostics. The company has raised $2.8 million from prominent investors, which supports its mission to enhance biosensor technology and pathway discovery through the integration of automation, computation, and synthetic biology.

Vitagene leverages big data and machine learning to provide personalized, actionable diet, fitness, and supplement recommendations to its members.

Conexio-Genomics is a privately operating life sciences company based in Fremantle, Western Australia. The company focuses on developing genetic sequencing and mutation detection products and services. Conexio-Genomics specializes in creating innovative solutions for typing that facilitate the matching of patients and donors in bone marrow or cord blood transplants. By leveraging advanced genetic technologies, the company aims to enhance the precision and effectiveness of transplant procedures, ultimately improving patient outcomes in the field of regenerative medicine.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50, and DAC, a diagnostic aid that enhances the resolution of cancer testing for patients with clinical suspicion of cancer. The company’s signature product is a multi-cancer early detection blood test that utilizes high-intensity sequencing to measure circulating nucleic acids, allowing for the identification of various cancer types at early stages. GRAIL is also working on developing minimal residual disease tests and other post-diagnostic assessments to further enhance cancer detection and treatment.

Helix is a prominent population genomics company that focuses on integrating genomic data into clinical care, research, and public health. Its comprehensive platform facilitates large-scale genetic analysis and actionable insights, serving health systems, life sciences companies, payers, and government organizations. Helix operates one of the largest CLIA and CAP-certified next-generation sequencing laboratories and employs its proprietary Exome+™ assay to support various aspects of population genomics. This includes recruitment and engagement, clinically actionable disease screening, and the return of results, as well as basic and translational research. By advancing genomic research and enhancing patient care, Helix plays a critical role in shaping healthcare through genetics.

GenoLogics, Inc. is a company that specializes in laboratory information management systems designed to enhance the diagnosis and treatment of diseases. Based in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers the BaseSpace Clarity LIMS, a solution utilized by research and clinical laboratories to efficiently track samples from receipt to result. This system aims to reduce costs, improve accuracy, and ensure rigorous quality control. The company focuses on translational medicine, genomics sequencing, systems biology research, and data management across multiple laboratories, facilitating collaborative initiatives in biomedical research. Founded in 2002, GenoLogics operates as a subsidiary of Illumina Inc., contributing to advancements in early disease detection, prevention, and treatment.

Twist Bioscience Corporation is a synthetic biology company based in South San Francisco, California, established in 2013. The company specializes in the production of synthetic DNA through its innovative DNA synthesis platform, which utilizes a proprietary semiconductor-based process on silicon chips. This approach allows for the rapid and cost-effective manufacturing of high-quality synthetic DNA, enabling applications in various fields, including healthcare, agriculture, industrial chemicals, and data storage. Twist Bioscience offers a range of products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA for digital data storage. The company aims to empower customers in their quest for solutions that improve lives and sustainability, positioning itself as a key player in accelerating advancements in synthetic biology.

Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomic powered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California.

NextBio is a privately owned software company based in Cupertino, California, that offers a web-based platform designed for life science researchers to search, discover, and share knowledge across both public and proprietary data. Co-founded in 2004 by Saeid Akhtari, Ilya Kupershmidt, and Mostafa Ronaghi, NextBio utilizes an ontology-based semantic framework that integrates diverse data types, including information on genes, tissues, diseases, and compounds. This framework allows researchers to access a comprehensive, searchable environment that correlates data from various organisms and research areas. The enterprise version of the platform is utilized by major pharmaceutical companies, enabling researchers and clinicians to upload and integrate proprietary data with publicly available information. This capability enhances the ability to identify relevant prognostic and predictive molecular signatures critical to their research. NextBio has attracted significant interest, with over 1.5 million visitors since its launch, and received recognition for its customer value enhancement in the life sciences sector.

Advanced Liquid Logic, Inc is a multidisciplinary team of scientists, engineers and product developers committed to providing unique workflow solutions to unmet challenges in laboratories and clinics. Dr. Michael Pollack and Dr. Vamsee Pamula founded the company in 2004 and remain engaged full time with the company as co-CTO’s. Vamsee and Michael developed the core technology while completing their doctorates and post doctoral research at Duke University’s Pratt School of Engineering. The company is led by an experienced CEO, Richard West, who joined ALL in 2005. Rich has 15 year’s experience as a CEO and a cumulative 30 years in business and product development management.

Moleculo is a biotech company specializing in advanced DNA sequencing technologies aimed at enhancing genome analysis. The company has created a novel sequencing method that delivers long and accurate reads, significantly improving the efficiency and precision of various DNA sequencing applications. This innovation allows clients to explore a broader array of applications in genomics, thereby advancing research and development in the field.

Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011.

BlueGnome Limited develops genetic diagnostic solutions for the screening of chromosomal abnormalities.

GenoLogics, Inc. is a company that specializes in laboratory information management systems designed to enhance the diagnosis and treatment of diseases. Based in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers the BaseSpace Clarity LIMS, a solution utilized by research and clinical laboratories to efficiently track samples from receipt to result. This system aims to reduce costs, improve accuracy, and ensure rigorous quality control. The company focuses on translational medicine, genomics sequencing, systems biology research, and data management across multiple laboratories, facilitating collaborative initiatives in biomedical research. Founded in 2002, GenoLogics operates as a subsidiary of Illumina Inc., contributing to advancements in early disease detection, prevention, and treatment.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.

Affomix has proprietary technology for rapid, automated, high-throughput selection of human monoclonal antibodies (mAbs). Their mission is to commercialize proprietary mAbs, mAb microarrays and mAb libraries for research, drug discovery, diagnostic and therapeutic applications, with a particular focus on the use of their mAbs for sensitive and accurate measurement of very large numbers of proteins in biological samples.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.